All In Biotech

Free tool

FAERS Monitor: Rydapt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207997 or its brand name (Rydapt, Midostaurin). Reports on generic versions are filed under their own applications.

Reports

1,957

Serious

1,424

73% of reports

Hospitalization

506

Death reported

472

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death329
  • nausea166
  • vomiting105
  • drug ineffective100
  • acute myeloid leukaemia recurrent93
  • pancytopenia93
  • pyrexia91
  • diarrhoea90
  • febrile neutropenia78
  • bone marrow failure76
  • drug intolerance73
  • lymphadenopathy60
  • platelet count decreased57
  • skin toxicity57
  • malignant neoplasm progression53

Reports by year received

View as table
YearReports
2017182
2018299
2019342
2020365
2021280
2022160
2023148
202484
202537
202660

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,202 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute myeloid leukaemia recurrentSignal93486.6397.242,658
skin toxicitySignal57109.584.75,961
bone marrow failureSignal7640.332.42,869
lymphadenopathySignal6018.214.2961
pancytopeniaSignal9317.914.71,470
febrile neutropeniaSignal7812.710.2827
drug intoleranceSignal738.16.5451
platelet count decreasedSignal575.84.5220
malignant neoplasm progressionSignal535.64.3195
deathSignal3294.13.7802
pyrexiaSignal912.82.3107
vomitingSignal1052.42.086
nauseaSignal1662.31.9119
diarrhoea901.51.215
drug ineffective1000.80.74

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.